ACIP Votes to Update Recommendations for HPV, Tdap, MenB, and HepB Vaccines

On October 19–20, CDC’s Advisory Committee on Immunization Practices (ACIP) met in Atlanta and voted to update several of its existing vaccine recommendations. Some of the changes are described below.

Human Papillomavirus (HPV) Vaccine
ACIP voted to change the HPV vaccination schedule from a 3-dose to a 2-dose series for adolescents who begin the HPV series at 9 through 14 years of age, regardless of age at series completion. Those who start the series later, at 15 through 26 years of age, or who are immunocompromised, will continue to need 3 doses.

The 9vHPV vaccine (HPV9, Gardasil 9, Merck) will soon be the only HPV vaccine available in the U.S. As of October 2016, Merck is distributing only HPV9, and supplies of 2vHPV (Cervarix, GSK) in the U.S. are now depleted. HPV9 may be used to complete a series begun with 4vHPV (HPV4, Gardasil, Merck) or 2vHPV.

Meningococcal Serogroup B Vaccine
Bexsero (MenB-4C, GSK) has previously been recommended by ACIP for use as a 2-dose series for high-risk individuals and in outbreak settings, and may also be administered to healthy individuals age 16 through 23 years. In April, FDA approved a label change giving MenB-FHbp (Trumenba, Pfizer) as either a 2-dose (0, 6 months) or 3-dose (0, 1–2, 6 months) series. ACIP voted to recommend that healthcare providers who use Trumenba continue to use the 3-dose series when vaccinating people at increased risk of meningococcal serogroup B disease (e.g., people with persistent complement component deficiencies or anatomic or functional asplenia) or during serogroup B outbreaks. The 2-dose series of Trumenba can be used for routine vaccination for healthy people age 16 through 23 years.

Tdap Vaccine
Previous ACIP recommendations called for prenatal care providers to vaccinate all pregnant women with Tdap vaccine during each pregnancy with optimal timing for this dose designated between 27 and 36 weeks gestation. In October, ACIP voted to recommend administering Tdap vaccination early in the 27- through 36-week “window” to maximize passive antibody transfer to the infant. The new recommendations also clarify that children age 7 through 10 years who receive Tdap as part of a catch-up series may be given an additional Tdap for the routinely recommended adolescent dose at 11–12 years of age.

Hepatitis B Vaccine
ACIP voted to announce a new guidance document that consolidates all previously published recommendations into a comprehensive statement. The committee reemphasized the importance of the HepB birth dose as a safety net against chronic HBV infection, now recommending that all newborns of HBsAg-negative (hepatitis B surface antigen-negative) mothers should be vaccinated with HepB vaccine within 24 hours of birth.

What’s In This Issue
ACIP Votes to Update Recommendations .......... 1
Ask the Experts: CDC Answers Your Questions ... 1
Vaccine Highlights ........................................ 5
New! MenB Vaccine: CDC Answers Questions ... 6
Updated! MenB Vaccine Recommendations by Age and Risk Factor ..................... 8
Updated! Standing Orders for MenB Vaccine ... 9
Updated! MenACWY Vaccine Recommendations by Age and Risk Factor .......... 10
Standing Orders for MenACWY Vaccines ...... 11
Resources to Help Improve Your MenACWY Vaccine Counter .................................... 12
Updated! Meningococcal Q&As – for Patients ... 13
Meningococcal Handouts to Give to Patients ... 14
What If You Don’t Vaccinate Your Child? ........... 15
Which Vaccines Do I Need Today? .................. 16
A Screening Form for Adults ............................ 16
Updated! IAC’s Temperature Logs ...................... 17
Use this Checklist to Protect Your Vaccines ... 18
Vaccine Handling Tips ..................................... 19
Products You Can Purchase from IAC ............... 20
Please Donate to IAC! ...................................... 21
IAC’s Immunization Resources Order Form ....... 22

Ask the Experts
The Immunization Action Coalition extends thanks to our experts, medical officer Andrew T. Kroger, MD, MPH, and nurse educator Donna L. Weaver, RN, MN, both with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention (CDC).

HPV vaccine
What is the new HPV vaccine schedule recommendation?
In October 2016, the Advisory Committee on Immunization Practices (ACIP) voted to recommend a routine 2-dose HPV vaccine schedule for adolescents who start the vaccination series before the 15th birthday. The two doses should be separated by 6–12 months (the minimum interval between doses is 5 months). A 3-dose schedule continues to be recommended for people who start the series on or after the 15th birthday and for people with certain immunocompromising conditions (such as cancer, HIV infection, or taking immunosuppressive drugs). A revised ACIP statement is being prepared and is expected to be published in December 2016.

Has ACIP expressed a preference for the 2-dose over the 3-dose schedule for adolescents 9 through 14 years of age?
Yes. ACIP recommends the 2-dose schedule for people starting the HPV vaccination series before the 15th birthday, as long as they are immunocompetent.

Does the 2-dose HPV vaccine schedule need to be completed with the same vaccine, or can it include different vaccines (such as bivalent or quadrivalent vaccine)?
The 2-dose schedule can be completed with any combination of HPV vaccine brands as long as dose #1 was given before age 15 years. Dose #2 should be administered 6–12 months after dose #1. If dose #1 of HPV vaccine was given before the 15th birthday and it has been more than a year since that dose was given, would the series be complete with just one additional dose?
Yes. Adolescents and adults who started the HPV vaccine series prior to the 15th birthday and who are not immunocompromised are considered to

Immunization questions?
▶ Email nipinfo@cdc.gov
▶ Call your state health department (phone numbers at www.immunize.org/ coordinators)
Ask the Experts…continued from page 1

adequately vaccinated with just one additional dose of HPV vaccine.

We have adolescents in our practice who have received the first 2 doses of the HPV series 1 or 2 months apart according to the 3-dose schedule. Can we consider their HPV vaccine series to be complete or do we need to give these patients a third dose?

People who have received 2 doses of HPV vaccine separated by less than 5 months should receive a third dose 6–12 months after dose #1 and at least 12 weeks after dose #2.

Will the 2-dose recommendation be retroactive for children and teens vaccinated prior to 2016?

Yes. Any person who ever received 2 doses of any combination of HPV vaccines can be considered fully vaccinated if dose #1 was given before the 15th birthday and the 2 doses were separated by at least 5 months.

MenACWY vaccine

Please review the new recommendations for use of MenACWY vaccine in people with human immunodeficiency virus (HIV) infection.

A growing body of evidence supports an increased risk for meningococcal disease in HIV-infected people. The Advisory Committee on Immunization Practices (ACIP) recommends that all HIV-infected people 2 months of age and older should routinely receive an age-appropriate MenACWY vaccine (Menactra, Sanofi Pasteur; Menveo, GSK). Children younger than age 2 years should be vaccinated using a multidose schedule (see the IAC educational piece “Meningococcal Vaccine Recommendations by Age and Risk Factor for Serogroups A, C, W, or Y Protection” available at www.immunize.org/catg.d/p2018.pdf for details).

People age 2 years and older with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY vaccine (doses separated by 8–12 weeks). People with HIV infection who have previously received one dose of MenACWY should receive a second dose at the earliest opportunity (at least 8 weeks after the previous dose) and then receive booster doses at the appropriate intervals. If the most recent dose was received before age 7 years, a booster dose should be administered 3 years later. If the most recent dose was received at age 7 years or older, a booster should be administered 5 years later and every 5 years thereafter throughout life.

I have an HIV-positive 64-year-old patient who received MenACWY vaccine last week. Was this the correct vaccine for this patient or should he have gotten meningococcal polysaccharide vaccine (MPSV4, Sanofi Pasteur) due to his age? Also, should this patient get another dose in 2 months?

MenACWY was the correct vaccine in this situation. The 2013 ACIP recommendations on MenACWY vaccination recommend the use of meningococcal conjugate vaccine in adults age 56 years and older who were vaccinated previously with MenACWY and now need revaccination, or are recommended to receive multiple doses. A person of this age with HIV infection should receive 2 doses of MenACWY separated by 8–12 weeks. Both MenACWY vaccines are licensed for use in people through age 55 years, which means that the use of these vaccines in people age 56 and older is off-label but recommended by ACIP.

I have a 24-month-old patient with HIV infection and I want to use Menactra (Sanofi Pasteur) because this is the only vaccine we have available in our clinic. However, this child received DTaP vaccine yesterday at another clinic. Can I administer Menactra today?

ACIP recommends that you wait 4 weeks from the dose of DTaP to administer the dose of Menactra. This is because data suggest a reduced response to the Menactra if given within a month after DTaP. If Menactra is to be administered to a child at increased risk for meningococcal disease, including children who have HIV infection, Menactra should be given either before or at the same visit as DTaP. Menveo brand MenACWY vaccine (GSK) can be given at any time before or after DTaP.

I have a 24-month-old patient with a complement component deficiency who received a dose of DTaP at 23 months of age and then received a dose of Menactra two weeks later. Do I need to repeat the dose of Menactra?

No. Even though ACIP recommends that Menactra should be given no less than 4 weeks after a dose of DTaP, there is no evidence to support repeating the dose of Menactra. A child with a complement component deficiency should still receive a second dose of MenACWY vaccine 8 weeks after the first dose.

Ask the Experts…continued on page 3 ▶

Subscribe to IAC Express, the Immunization Action Coalition’s e-news and information service at www.immunize.org/subscribe

DISCLAIMER: Needle Tips is available to all readers free of charge. Some of the information in this issue is supplied to us by the Centers for Disease Control and Prevention in Atlanta, Georgia, and some information is supplied by third-party sources. The Immunization Action Coalition (IAC) has used its best efforts to accurately publish all of this information, but IAC cannot guarantee that the original information as supplied by others is correct or complete, or that it has been accurately published. Some of the information in this issue is created or compiled by IAC. All of the information in this issue is of a time-critical nature, and we cannot guarantee that some of the information is not now outdated, inaccurate, or incomplete. IAC cannot guarantee that reliance on the information in this issue will cause no injury. Before you rely on the information in this issue, you should first independently verify its current accuracy and completeness. IAC is not liable to practice medicine or pharmacology, and the providing of the information in this issue does not constitute such practice. Any claim against IAC must be submitted to binding arbitration under the auspices of the American Arbitration Association in Saint Paul, Minnesota.
Ask the Experts...continued from page 2

Does the recommendation about separation of DTaP and Menactra also apply to children with functional or anatomic asplenia?

Yes. The recommendation about spacing of DTaP and Menactra (described above) applies to children of any age with a high-risk condition for meningococcal disease, including travelers.

The ACIP MenACWY vaccine recommendations state that a routine second dose needs to be given at 16 years of age. Children with asplenia or other high-risk conditions should receive a booster dose every 5 years. If a child with a high-risk condition receives a dose of MenACWY at age 9 years (and a second primary dose 8 weeks later), should they receive a booster dose at age 14 years (5 years after the primary series), or should they receive a dose at age 16 years as recommended in the routine schedule?

The MenACWY booster dose should be given at 14 years (5 years after the primary series) and every 5 years thereafter. The every 5-year booster dose schedule for persons with high-risk conditions takes precedence over the routine second dose schedule.

MenB vaccine

Which individuals in risk groups are recommended to be vaccinated against meningococcal serogroup B disease?

CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine MenB vaccination of the following individuals in certain risk groups:

- People age 10 years and older who have functional or anatomic asplenia
- People age 10 years and older who have persistent complement component deficiency, including people taking eculizumab (Soliris)
- People age 10 years and older who are at risk during an outbreak caused by a vaccine serogroup, such as on a college campus
- Microbiologists who work with meningococcus bacteria in a laboratory

Both MenB vaccines are licensed for use in people through age 25 years, which means that the use of these vaccines in people age 26 and older is off-label but recommended by ACIP.

What is the new schedule for Trumenba MenB vaccine?

The Food and Drug Administration approved a 2-dose schedule for Trumenba in April 2016. At its October 2016 meeting, ACIP voted to recommend a 2-dose schedule of Trumenba for people not at increased risk of MenB (for example, healthy adolescents). The two doses should be administered at least 6 months apart. ACIP recommends that people at increased risk of MenB disease (complement component deficiency, functional or anatomic asplenia, at risk during an outbreak of meningococcal B disease, and certain microbiologists) receive a 3-dose Trumenba series with dose #2 and dose #3 administered 2 and 6 months after dose #1.

The schedule for Bexsero has not changed. Bexsero is a 2-dose series with dose #2 given at least 1 month after dose #1.

Should college students be vaccinated against meningococcal B disease?

Although several small meningococcal serogroup B disease outbreaks have occurred on college campuses since 2013, college students in general are not at higher risk of meningococcal B disease then people of the same age who are not college students. Consequently,
Influenza vaccine

Please provide details about the use of FluLaval influenza vaccine (GlaxoSmithKline) in children younger than 3 years.

On November 18, 2016, the Food and Drug Administration approved an extension of the age range of quadrivalent FluLaval (inactivated influenza vaccine, GSK) to include children 6 through 35 months of age. FluLaval was previously approved for people 3 years of age and older. The approval of the extended age range for FluLaval was based on a study showing an equivalent (“non-inferior”) response compared to children who received Fluzone (Sanofi Pasteur) pediatric formulation. The vaccine will be supplied for this indication in manufacturer-filled syringes and multi-dose vials. The dosage approved for children 6 through 35 months of age is 0.5 mL – the same dosage as for people 3 years of age and older.

ACIP has not yet issued a recommendation regarding the use of FluLaval in children 6 through 35 months of age. However, clinicians are free to use this and other vaccines in a manner consistent with their labeling.

Can a child 6 through 35 months of age who needs 2 doses of influenza vaccine this season receive one each of Fluzone Pediatric and FluLaval vaccine?

Yes. Both Fluzone Pediatric (0.25 mL dose) and FluLaval (0.5 mL dose) are approved by the Food and Drug Administration for use in children 6 through 35 months of age.

A 2-year-old was inadvertently given a 0.25 mL dose of FluLaval rather than the recommended 0.5 mL dose. What should we do?

If the error is discovered while the child is still in the office you can administer the other “half” of the FluLaval dose. If the error is discovered later, then the child should be recalled to the office and given a full age-appropriate repeat dose, either a 0.5 mL dose of FluLaval or a 0.25 mL dose of Fluzone.

Can a clinic vaccinate children younger than age 3 years with influenza vaccine taken from a multidose vial of Fluzone or FluLaval? The multi-dose vials contain thimerosal as a preservative.

Yes. Multidose vials of Fluzone and FluLaval contain a small amount of thimerosal to prevent bacterial and fungal growth in the vial. Thimerosal-containing vaccines are safe to use in children. No scientific evidence indicates that thimerosal in vaccines causes adverse events unless the patient has a severe allergy to thimerosal. However, a few states have enacted legislation that restricts the use of thimerosal-containing vaccines in children. To find out if your state has such restrictions, check with your state immunization program (see www.immunize.org/coordinates for phone numbers).

Needle Tips correction policy

If you find an error, please notify us immediately by sending an email message to admin@immunize.org. We publish notification of significant errors in our email announcement service, IAC Express. Be sure you’re signed up for this service. To subscribe, visit www.immunize.org/subscribe.